Medivir AB: Tibotec Pharmaceuticals Ltd Files Application To Start A Phase I Clinical Trial For HCV Inhibitor
STOCKHOLM, Sweden--(BUSINESS WIRE)--Tibotec Pharmaceuticals Inc, on behalf of the Medivir (STO:MVIRB) and Tibotec collaborative drug discovery project on hepatitis C virus (HCV), has filed an application with a European regulatory authority to commence the first phase I clinical trial of an HCV NS3/4A protease inhibitor. This trial is estimated to begin during Q1/2007. The collaboration was initiated in November 2004. This milestone triggers a payment of EUR 2.5 million to Medivir.